A detailed history of Charles Schwab Investment Management Inc transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,401,628 shares of BMRN stock, worth $93.4 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,401,628
Previous 1,345,929 4.14%
Holding current value
$93.4 Million
Previous $111 Million 11.09%
% of portfolio
0.02%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$69.02 - $93.84 $3.84 Million - $5.23 Million
55,699 Added 4.14%
1,401,628 $98.5 Million
Q2 2024

Aug 12, 2024

BUY
$74.43 - $92.22 $343,420 - $425,503
4,614 Added 0.34%
1,345,929 $111 Million
Q1 2024

May 08, 2024

SELL
$83.81 - $99.0 $3.15 Million - $3.72 Million
-37,582 Reduced 2.73%
1,341,315 $117 Million
Q4 2023

Feb 06, 2024

BUY
$76.22 - $98.51 $5.65 Million - $7.3 Million
74,100 Added 5.68%
1,378,897 $133 Million
Q3 2023

Nov 08, 2023

BUY
$85.07 - $94.48 $2.86 Million - $3.17 Million
33,592 Added 2.64%
1,304,797 $115 Million
Q2 2023

Aug 09, 2023

BUY
$86.68 - $100.3 $1.06 Million - $1.22 Million
12,173 Added 0.97%
1,271,205 $110 Million
Q1 2023

May 11, 2023

BUY
$87.74 - $117.27 $1.5 Million - $2 Million
17,052 Added 1.37%
1,259,032 $122 Million
Q4 2022

Feb 13, 2023

BUY
$80.93 - $108.63 $2.18 Million - $2.93 Million
26,963 Added 2.22%
1,241,980 $129 Million
Q3 2022

Nov 14, 2022

BUY
$82.16 - $96.94 $1.06 Million - $1.25 Million
12,907 Added 1.07%
1,215,017 $103 Million
Q2 2022

Aug 15, 2022

BUY
$71.48 - $86.85 $5.3 Million - $6.43 Million
74,080 Added 6.57%
1,202,110 $99.6 Million
Q1 2022

May 13, 2022

BUY
$74.28 - $92.69 $2.01 Million - $2.51 Million
27,091 Added 2.46%
1,128,030 $87 Million
Q4 2021

Feb 11, 2022

BUY
$71.72 - $91.47 $3.55 Million - $4.53 Million
49,535 Added 4.71%
1,100,939 $97.3 Million
Q3 2021

Nov 16, 2021

BUY
$74.77 - $85.47 $32.5 Million - $37.2 Million
435,084 Added 70.59%
1,051,404 $81.3 Million
Q2 2021

Aug 16, 2021

BUY
$75.51 - $84.79 $2.63 Million - $2.96 Million
34,886 Added 6.0%
616,320 $51.4 Million
Q1 2021

May 17, 2021

SELL
$74.73 - $90.69 $8.43 Million - $10.2 Million
-112,796 Reduced 16.25%
581,434 $43.9 Million
Q4 2020

Feb 16, 2021

BUY
$72.61 - $90.2 $856,289 - $1.06 Million
11,793 Added 1.73%
694,230 $60.9 Million
Q3 2020

Nov 13, 2020

BUY
$71.87 - $131.03 $4.31 Million - $7.86 Million
60,022 Added 9.64%
682,437 $51.9 Million
Q2 2020

Aug 14, 2020

BUY
$79.55 - $124.22 $2.05 Million - $3.2 Million
25,784 Added 4.32%
622,415 $76.8 Million
Q1 2020

May 15, 2020

BUY
$71.37 - $96.85 $1.5 Million - $2.04 Million
21,061 Added 3.66%
596,631 $50.4 Million
Q4 2019

Feb 07, 2020

BUY
$64.27 - $86.37 $5.41 Million - $7.27 Million
84,123 Added 17.12%
575,570 $48.7 Million
Q3 2019

Nov 08, 2019

BUY
$67.4 - $85.11 $1.59 Million - $2.01 Million
23,637 Added 5.05%
491,447 $33.1 Million
Q2 2019

Aug 09, 2019

BUY
$80.35 - $93.9 $1.8 Million - $2.1 Million
22,343 Added 5.02%
467,810 $40.1 Million
Q1 2019

May 14, 2019

BUY
$84.2 - $98.62 $2.23 Million - $2.61 Million
26,427 Added 6.31%
445,467 $39.6 Million
Q4 2018

Feb 14, 2019

BUY
$80.14 - $106.07 $1.83 Million - $2.42 Million
22,812 Added 5.76%
419,040 $35.7 Million
Q3 2018

Nov 13, 2018

BUY
$93.92 - $105.72 $1.96 Million - $2.21 Million
20,862 Added 5.56%
396,228 $38.4 Million
Q2 2018

Aug 08, 2018

BUY
$76.01 - $99.03 $1.57 Million - $2.05 Million
20,685 Added 5.83%
375,366 $35.4 Million
Q1 2018

May 07, 2018

BUY
$77.67 - $92.63 $1.46 Million - $1.74 Million
18,782 Added 5.59%
354,681 $28.8 Million
Q4 2017

Jan 17, 2018

BUY
$80.76 - $95.13 $1.24 Million - $1.47 Million
15,414 Added 4.81%
335,899 $30 Million
Q3 2017

Nov 13, 2017

BUY
$80.6 - $94.95 $25.8 Million - $30.4 Million
320,485
320,485 $29.8 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.